|
Outbreak of Measles --- Venezuela and Colombia, 2001--2002
Substantial progress has been made toward interrupting indigenous measles
transmission in the Region of the Americas (1--4).
In 2001, the number of confirmed measles cases in the region reached a
record low of 537 cases, a 99% decrease since 1990 (4).
During 2001, the Dominican Republic and Haiti interrupted indigenous measles
transmission successfully (4,5),
ending known indigenous transmission of the D6 measles virus genotype. This
genotype, which had circulated widely in the Region of the Americas since
1995, caused nationwide outbreaks in Argentina, Bolivia, Brazil, the
Dominican Republic, and Haiti during 1997--2001 (3--7).
In August 2001, a measles outbreak introduced by a traveler returning from
Europe occurred in Venezuela and was exported to Colombia in 2002. This
report describes the epidemiology of the outbreaks and control measures
implemented by the ministries of health of Venezuela and Colombia.
Venezuela
In 2000, measles vaccination coverage in Venezuela was 84% on the basis
of administrative data reported routinely. By September 2001, estimated
coverage had decreased to 58% and was lower in Venezuelan states near the
border with northern Colombia (e.g., Falcón, 44%; Zulia, 34%) (Figure
1).
During 2001--2002, two outbreaks of measles occurred in Venezuela. On
August 29, 2001, a man aged 39 years (index case) had rash onset of measles
1 day before returning to Falcón from a trip to Switzerland, Germany, and
Spain during August 4--30. Approximately 1 month later, an investigation was
initiated by local health authorities to identify additional cases. The
first laboratory-confirmed case was reported on September 28 and occurred in
the index patient's brother, aged 35 years, who had rash onset on September
23. The majority of persons who were affected by the outbreak were
health-care workers, laborers, and students. The outbreak lasted until
December 15, affected 37 persons in three municipalities, and ended after
implementation of a statewide vaccination campaign for children aged 1--14
years.
In January 2002, a second outbreak of measles was introduced into Falcón
from Zulia by a girl aged 7 months who had visited a tourist site in Falcón
and who had received medical care at a local hospital. She infected a nurse,
who then transmitted the disease to other persons. Of 165 persons reported
from Falcón during this outbreak, 85 (52%) had visited the same tourist
site.
The first confirmed measles case in Zulia occurred in a woman aged 27
years who was an auxiliary nurse in a physician's office that provided care
to residents of Falcón. The nurse had onset of rash on October 25, 2001, and
subsequently infected four other persons. During the next 3 months, the
outbreak spread to all municipalities in Zulia; 2,074 cases had been
confirmed as of July 24, 2002. For several chains of transmission, the index
case occurred in a health-care worker. Beginning in February 2002, the
outbreak spread to 14 additional states in Venezuela, including four states
bordering Colombia.
During October 2001--July 2002, Venezuela reported 6,380 suspected
measles cases; of these, 2,416 were laboratory or epidemiologically
confirmed.* The outbreak peaked during the week of March 16 (week 11) (Figure
2) and has affected 16 (67%) of the 24 states in Venezuela. A total of
2,074 (86%) cases were from Zulia, 202 (8%) from Falcón, and 140 (4%) from
the other 14 states. The age groups most affected were children aged <1 year
(120 cases per 100,000 population), children aged 1--4 years (26), and
persons aged 20--24 years (12) (Figure 3).
During November 2001--January 2002, measles virus samples were collected
from patients in Zulia. Genetic sequencing indicated that the virus was not
similar to viruses encountered previously in the region or to the reference
genotype strains available on the measles sequence database. A close match
was identified from virus samples taken from cases imported into Australia
from Indonesia as early as 1999, which have been given the proposed
designation of genotype d9 (D. Chibo, Ph.D., World Health
Organization, Measles Reference Laboratory [Western Pacific Region],
Australia, personal communication, 2002).
During November 2001--January 2002, a follow-up measles vaccination
campaign was implemented targeting approximately 2.2 million children aged
1--4 years; 16 of the 24 states reported coverage of 100%. However, the
outbreak continued with cases occurring in all age groups. House-to-house
monitoring of vaccination coverage revealed areas with unvaccinated
children. In March 2002, a nationwide vaccination campaign was implemented
targeting approximately 5.5 million children aged 6 months--14 years and an
estimated 5.5 million adults at high risk (e.g., health-care workers,
tourists, factory workers, soldiers, university students, and migrants) in
urban, periurban (densely populated informal settlements), and rural areas.
Vaccination coverage among adults at high risk in that campaign was
estimated to be 76% as of July 6 (week 27).
Colombia
Colombia shares a border with Venezuela, with which it has substantial
commerce and migration in Zulia. In 1996, measles vaccination coverage for
children in Colombia was 94%. In 2000, measles coverage for children aged 1
year declined to 80%. Coverage for children aged 1 year increased to 91%
during 2001.
In January 2002, the first confirmed case occurred in a girl aged 7 years
from Colombia. She had rash onset on January 20 and reported previous
contact in Zulia with persons with confirmed measles. As of July 6 (week
27), 68 cases have been confirmed (Figure 4). Confirmed
cases have occurred in 19 municipalities in 10 (30%) of the 33 departments;
17 affected municipalities were located on the Atlantic coast and/or
bordered Venezuela. As of July 18, the most recent confirmed patient had
rash onset on July 17 (week 29). Of the 68 confirmed cases, 18 (26%) were
imported from Venezuela, 35 (51%) were epidemiologically linked to those
importations, nine (13%) were from unknown sources, and six (9%) are under
investigation. Of 44 patients aged 1--4 years, 15 (34%) had received measles
vaccine previously. The age groups most affected were children aged <5 years
(0.7 per 100,000 population), children aged 5--9 years (0.2), and persons
aged 25--29 years (0.1) (Figure 3).
Control activities being implemented include 1) door-to-door measles
vaccination campaigns in high-risk municipalities as part of a national
vaccination campaign for approximately 3.8 million children aged 6 months--5
years and other adults at high risk (e.g., health-care workers, migrants,
and travelers), 2) house-to-house vaccination coverage monitoring in areas
at high risk, 3) strengthening of national measles surveillance, and 4)
increased training in case investigation and outbreak control. As of July
10, 2002, a total of 2,587,408 (73%) children in the target group had been
vaccinated.
During these outbreaks, measles surveillance has been heightened by using
active case searches in both countries, with 2,198 suspected cases detected
(5.4 per 100,000 population) in Colombia and 6,380 (26.5) in Venezuela.
Technical and financial resources have been provided by international
organizations, including Pan American Health Organization, United Nations
Children's Fund (UNICEF), and CDC.
Reported by: H Izurieta, M Brana, P Carrasco, V Dietz, G
Tambini, CA de Quadros, Div of Vaccines and Immunizations; Pan American
Health Organization, Washington, DC. O Barrezueta, Pan American Health
Organization; N López, D Rivera, L López, M Villegas, E Maita, Ministry of
Health; C Garcia, National Institute of Hygiene, Caracas, Venezuela. D
Pastor, Pan American Health Organization; C Castro, J Boshell, O Castillo, G
Rey, F de la Hoz, D Caceres, M Velandia, National Institute of Health,
Ministry of Health, Bogotá, Colombia. W Bellini, J Rota, P Rota, Div of
Viral and Rickettsial Diseases, National Center for Infectious Diseases; F
Lievano, C Lee, Global Immunization Div, National Immunization Program, CDC.
Editorial Note:
The reintroduction of measles and its subsequent transmission in
Venezuela and exportation to Colombia indicates that, until global measles
eradication is achieved, countries in the Region of the Americas are
vulnerable to importations. However, these importations should not result in
sustained measles transmission if vaccination coverage is maintained at high
levels (>95%) in all municipalities and follow-up campaigns are conducted on
time (3,4).
Low vaccination coverage in Venezuela and deficiencies in surveillance
contributed to the outbreak. The first report of a case was delayed for
approximately 1 month, sufficient time for the occurrence of several
generations of transmission and spread to other areas.
Colombia initiated aggressive vaccination activities in 2001 when
Venezuela began reporting cases. The limited transmission in Colombia
suggests that efforts to prevent a large outbreak might have been
successful. However, because of civil conflict in several areas, confirming
the lack of virus transmission was difficult. In addition, a contributing
factor to lower transmission in Colombia might have been the higher measles
coverage rates before the outbreak compared with Venezuela.
Measures to control measles outbreaks in the Region of the Americas
include 1) partnerships with local governments to secure financial and
logistical resources, 2) rapid identification and vaccination of groups at
high risk (e.g., health-care workers, migrants, and tourist industry
personnel), 3) house-to-house monitoring of vaccination coverage, 4)
expansion of the target group to older ages if incidence is high in these
age cohorts, and 5) heightened surveillance in all regions of the country.
References
- de Quadros CA, Olivé JM, Hersh BS, et al. Measles elimination in the
Americas---evolving strategies. JAMA 1996;275:224--9.
- Pan American Health Organization. Elimination of measles in the
Americas. Washington, DC: XXIV Meeting of the Pan American Sanitary
Conference, 1995.
- Pan
American Health Organization. Progress toward interrupting indigenous
measles transmission---Region of the Americas, January 1999 --September
2000. MMWR 2000;49:986--90.
- CDC.
Progress toward interrupting indigenous measles transmission---Region of
the Americas, January--November 2001. MMWR 2001;50:1133.
- Pan American Health Organization, Division of Vaccines and
Immunization. Haiti begins all out effort to halt measles and OPV-derived
polio outbreaks. EPI Newsletter 2001;22:2.
- Oliveira MI, Rota PA, Curti SP, et al. Genetic homogeneity of measles
viruses associated with a measles outbreak, São Paulo, Brazil, 1997. Emerg
Infect Dis 2002;8:808--13.
- de Quadros CA, Izurieta HS, Carrasco P, Brana M, Tambini G. Progress
towards measles eradication in the Region of the Americas. J Infect Dis
2003(in press).
* Epidemiologically linked to another laboratory-confirmed measles case.
The lowercase letter is used for newly identified measles
genotypes, pending an update of measles genotypes in the World Health
Organization Weekly Epidemiological Record.
Use of trade names and commercial sources is for
identification only and does not imply endorsement by the U.S.
Department of Health and Human Services.
References to non-CDC sites on the Internet are provided as a service
to MMWR readers and do not constitute or imply endorsement of
these organizations or their programs by CDC or the U.S. Department of
Health and Human Services. CDC is not responsible for the content of
pages found at these sites. URL addresses listed in MMWR were
current as of the date of publication.
|
All MMWR HTML versions of articles are electronic
conversions from ASCII text into HTML. This conversion may have resulted in
character translation or format errors in the HTML version. Users should not
rely on this HTML document, but are referred to the electronic PDF version
and/or the original MMWR paper copy for the official text, figures,
and tables. An original paper copy of this issue can be obtained from the
Superintendent of Documents, U.S. Government Printing Office (GPO),
Washington, DC 20402-9371; telephone: (202) 512-1800. Contact GPO for
current prices.
**Questions or messages regarding errors in formatting should be
addressed to mmwrq@cdc.gov.
Page converted: 8/29/2002
|
|